|
Accession number;01A0607669
|
| Title;Condition for Use of Antidiabetic Drugs and Side Effects. |
| Author;
YAMASAKI MIHO
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
KONISHI TOSHIO
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
MAEDA YORINOBU
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
SAIONJI SHINJI
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
TAKEDA YOSHIAKI
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
FUKUHARA SHINJI
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
ARIHARA SHOKO
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
TSUKIAI SATSUKI
(Rodofukushijigyodan Chugokurosaibyoin Yakuzaibu)
MARUHASHI AKIRA
(Rodofukushijigyodan Chugokurosaibyoin Naika)
|
Journal Title;Japanese Journal of Pharmaceutical Health Care and Sciences
|
Journal Code:Y0888A
|
ISSN:1346-342X
|
|
VOL.27;NO.3;PAGE.291-297(2001)
|
| Figure&Table&Reference;FIG.7, TBL.7, REF.4 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We reviewed the medical charts and conducted a questionnaire survey of 298 outpatients to examine the use of antidiabetic drugs and side effects. Of the first prescribed medicines, the ratio of Rastinon (tolbutamide) was the highest and about 90% were sulfonylureas. At present, 52% of the prescribed medicines are sulfonylureas, 21% are sulfonylureas and either an .ALPHA.-glucosidase inhibitor or a reducer of insulin resisitance, while 11% receive insulin. The side effects of these antidiabetic drugs include hypoglycemia by sulfonylureas or insulin, digestive symptoms due to .ALPHA.-glucosidase inhibitor, among others. (author abst.) |
|
|
|
Related Articles;
|
